Cooperation of side population cells with CD133 to enrich cancer stem cells in a laryngeal cancer cell line

Head and Neck

Volumn 36, Issue 9, 2014, Pages 1279-1287

  Wu, Chun Ping ^a   Xie, Ming ^a   Zhou, Liang ^a   Tao, Lei ^a   Zhang, Ming ^a   Tian, Jie ^b  

^a FUDAN UNIVERSITY   (China)

^b EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

AC133 antigen; human epithelial type 2 (Hep 2) cell line; laryngeal neoplasms; neoplastic stem cells; side population cells

Indexed keywords

CD133 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HEP 2 CELL LINE; HUMAN; HUMAN CELL; LARYNGEAL CANCER CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIDE POPULATION CELL; SPHEROID CELL;

EID: 84906085511     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23447     Document Type: Article

References (28)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
2. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
3. Cheng JX, Liu BL, Zhang X,. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 2009; 35: 403-408.
4. Wu YJ, Wu PY,. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009; 18: 1127-1134.
5. Moserle L, Ghisi M, Amadori A, Indraccolo S,. Side population and cancer stem cells: therapeutic implications. Cancer Lett 2010; 288: 1-9.
6. Tabor MH, Clay MR, Owen JH, et al. Head and neck cancer stem cells: the side population. Laryngoscope 2011; 121: 527-533.
7. Zhou L, Wei X, Cheng L, Tian J, Jiang JJ,. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007; 117: 455-460.
8. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
9. Meng X, Li M, Wang X, Wang Y, Ma D,. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 2009; 100: 1040-1046.
10. Mitsutake N, Iwao A, Nagai K, et al. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007; 148: 1797-1803.
11. Lichtenauer UD, Shapiro I, Geiger K, et al. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology 2008; 149: 1314-1322.
12. Bidlingmaier S, Zhu X, Liu B,. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) 2008; 86: 1025-1032.
13. Wan G, Zhou L, Xie M, Chen H, Tian J,. Characterization of side population cells from laryngeal cancer cell lines. Head Neck 2010; 32: 1302-1309.
14. Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ,., Maccallum J,. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 2009; 31: 94-101.
15. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
16. Pardal R, Clarke MF, Morrison SJ,. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
17. Polyak K, Hahn WC,. Roots and stems: stem cells in cancer. Nat Med 2006; 12: 296-300.
18. Rosen JM, Jordan CT,. The increasing complexity of the cancer stem cell paradigm. Science 2009; 324: 1670-1673.
19. Clevers H,. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-319.
20. Cui F, Wang J, Chen D, Chen YJ,. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep 2011; 25: 701-708.
21. Broadley K, Hunn MK, Farrand KJ, et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011; 29: 452-461.
22. Mueller T, Luetzkendorf J, Nerger K, Schmoll HJ, Mueller LP,. Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells. Cell Mol Life Sci 2009; 66: 495-503.
23. Ding XW, Wu JH, Jiang CP,. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010; 86: 631-637.
24. Siddique HR, Saleem M,. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012; 30: 372-378.
25. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH,. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007; 67: 3716-3724.
26. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
27. Camargo FD, Chambers SM, Drew E, McNagny KM, Goodell MA,. Hematopoietic stem cells do not engraft with absolute efficiencies. Blood 2006; 107: 501-507.
28. Challen GA, Boles NC, Chambers SM, Goodell MA,. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010; 6: 265-278.